Same Drug Class

Nivolumab vs Trastuzumab

Nivolumab vs Trastuzumab: Overview

This comparison examines the pharmacological differences between Nivolumab and Trastuzumab.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

Pharmacokinetics

Half-life: Nivolumab β€” 27 days; Trastuzumab β€” 28 days.

Chemical Properties

Type: Nivolumab β€” Antibody; Trastuzumab β€” Antibody.